|
 Writing in Annals of Internal Medicine, researchers at the
University of California, San Francisco (UCSF) call the industry’s
push into the smoking-cessation market “the pharmaceuticalization of
the tobacco industry.”
“The same hand that’s creating the problem is attempting to create
the solution,” lead author Yogi Hendlin said in a phone interview.
“But their solution is long-term nicotine maintenance, rather than
total tobacco cessation.”
Marketing tobacco-industry merchandise as pharmaceutical products
and devices threatens to endanger public health and to derail
decades of progress in educating the public about the risks of
smoking, his team's opinion piece says.
“Tobacco companies see their future as pharmaceutical companies.
They’ve already begun to acquire pharmaceutical subsidiaries, and
they’re producing tobacco products that look and feel like
medicines,” senior author Dr. Pamela Ling, a professor of medicine
at UCSF, said in a phone interview.
The authors define “pharmaceuticalization” as the tobacco industry’s
“actual and perceived transition into a pharmaceutical-like industry
through the manufacture and sale of noncombustible tobacco and
nicotine products for smoking cessation or long-term nicotine
maintenance without the testing and oversight required of
traditional pharmaceutical products.”
The effort confuses consumers, complicates the regulatory process
and legitimizes the tobacco industry as a healthcare partner, they
say.
In response, Philip Morris International told Reuters Health in a
statement that it understood that some might question its motives.
“At the same time we are very encouraged by the growing number of
experts and health authorities who believe that tobacco companies
like us have a key role to play in reducing the harm caused by
smoking,” the statement said.
“We are making significant efforts so that all those who would
otherwise continue smoking switch to scientifically substantiated
smoke-free alternatives as soon as possible,” it said. “We do not
ask to be trusted but to be judged based on facts.”
Ling, Hendlin and their coauthor Jesse Elias say the
pharmaceuticalization of tobacco relies on two false assumptions:
substantial numbers of smokers cannot quit, and the only way most
smokers could quit would be with the help of pharmacotherapy.
As many as 90 percent of smokers who stop smoking do so cold turkey,
without cessation aids, said Hendlin, a postdoctoral fellow at
UCSF’s Center for Tobacco Control Research and Education.
But quitting cold turkey is easier said than done for a substantial
group of smokers, particularly smokers coping with substance abuse
and other mental health issues, said Donna Vallone, chief research
officer at Truth Initiative’s Schroeder Institute, a Washington,
D.C. nonprofit dedicated to ending youth smoking.
[to top of second column] |
“Believe me, it’s right to worry about the industry’s objectives
here,” she said by phone.
“On the other hand, we do believe that harm reduction is a
legitimate public-health strategy. When you’re a lifetime committed
smoker and you’re trying to quit, these products can be helpful to
you,” said Vallone, who was not involved in the commentary.
All the major transnational tobacco companies have invested in
so-called pharmaceuticalized tobacco products, according to the
commentary authors.
In December, Philip Morris submitted a multimillion-page application
to the U.S. Food and Drug Administration (FDA) seeking to certify a
new product – I Quit Ordinary Smoking, or IQOS – as having “modified
risk” compared to cigarettes.
IQOS includes short, disposable tobacco sticks soaked in propylene
glycol and inserted in a heat-not-burn cigarette, which, like
e-cigarettes, exempts it from smoking laws in many countries. A
recent study in JAMA Internal Medicine found that the product
releases chemicals linked to cancer, sometimes in higher
concentrations than conventional cigarettes.
If approved by the FDA, IQOS would become the country’s first
modified-risk, or reduced-harm, tobacco product.
Smoke from IQOS cigarettes releases 84 percent of the nicotine found
in traditional cigarettes, the JAMA Internal Medicine study found.
“While the tobacco industry seeks to glamorize, normalize and
rationalize nicotine addiction, don’t be fooled: nicotine is a
potently addictive and harmful drug,” said Mark Travers, a
researcher at the Roswell Park Cancer Institute in Buffalo, New
York.
“Our ultimate goal will always be to end tobacco use AND nicotine
addiction,” said Travers, who was not involved with the commentary,
in an email. “Yes, pharmaceutical nicotine, as approved by the FDA,
is an effective way to assist in stopping smoking, but complete
abstinence of tobacco and nicotine use is the best outcome.”
SOURCE: http://bit.ly/2tkmP93 Annals of Internal Medicine, online
July 17, 2017.
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
